Cargando…
Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option?
BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259966/ https://www.ncbi.nlm.nih.gov/pubmed/35812101 http://dx.doi.org/10.3389/fneur.2022.884158 |
_version_ | 1784741907294846976 |
---|---|
author | Ricciardi, Luca Manini, Ivana Cesselli, Daniela Trungu, Sokol Piazza, Amedeo Mangraviti, Antonella Miscusi, Massimo Raco, Antonino Ius, Tamara |
author_facet | Ricciardi, Luca Manini, Ivana Cesselli, Daniela Trungu, Sokol Piazza, Amedeo Mangraviti, Antonella Miscusi, Massimo Raco, Antonino Ius, Tamara |
author_sort | Ricciardi, Luca |
collection | PubMed |
description | BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. OBJECTIVE: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. METHODS: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): “high grade glioma” [MeSH] AND “Carmustine” [MeSH] and free text terms: “surgery” OR “BCNU wafer” OR “Gliadel” OR “systemic treatment options” OR “overall survival.” RESULTS: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). CONCLUSIONS: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable. |
format | Online Article Text |
id | pubmed-9259966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92599662022-07-08 Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? Ricciardi, Luca Manini, Ivana Cesselli, Daniela Trungu, Sokol Piazza, Amedeo Mangraviti, Antonella Miscusi, Massimo Raco, Antonino Ius, Tamara Front Neurol Neurology BACKGROUND: The implantation protocol for Carmustine Wafers (CWs) in high grade glioma (HGG) was developed to offer a bridge between surgical resection and adjuvant treatments, such as radio- and chemotherapy. In the last years, however, a widespread use of CWs has been limited due to uncertainties regarding efficacy, in addition to increased risk of infection and elevated costs of treatment. OBJECTIVE: The aims of our study were to investigate the epidemiology of patients that underwent surgery for HGG with CW implantation, in addition to the assessment of related complications, long-term overall survival (OS), and associated prognostic factors. METHODS: Three different medical databases were screened for conducting a systematic review of the literature, according to the PRISMA statement guidelines, evaluating the role of BCNU wafer implantation in patients with newly diagnosed HGG. The search query was based on a combination of medical subject headings (MeSH): “high grade glioma” [MeSH] AND “Carmustine” [MeSH] and free text terms: “surgery” OR “BCNU wafer” OR “Gliadel” OR “systemic treatment options” OR “overall survival.” RESULTS: The analysis of the meta-data demonstrated that there was a significant advantage in using CWs in newly diagnosed GBM in terms of OS, and a very low heterogeneity among the included studies [mean difference 2.64 (95% CI 0.85, 4.44); p = 0.004; I2149 = 0%]. Conversely, no significant difference between the two treatment groups in terms of PFS wad detected (p = 0.55). The analysis of complications showed a relatively higher rate in Carmustine implanted patients, although this difference was not significant (p = 0.53). CONCLUSIONS: This meta-analysis seems to suggest that CWs implantation plays a significant role in improving the OS, when used in patients with newly diagnosed HGG. To minimize the risk of side effects, however, a carful patient selection based mainly on patient age and tumor volume should be desirable. Frontiers Media S.A. 2022-06-23 /pmc/articles/PMC9259966/ /pubmed/35812101 http://dx.doi.org/10.3389/fneur.2022.884158 Text en Copyright © 2022 Ricciardi, Manini, Cesselli, Trungu, Piazza, Mangraviti, Miscusi, Raco and Ius. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Ricciardi, Luca Manini, Ivana Cesselli, Daniela Trungu, Sokol Piazza, Amedeo Mangraviti, Antonella Miscusi, Massimo Raco, Antonino Ius, Tamara Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title | Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title_full | Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title_fullStr | Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title_full_unstemmed | Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title_short | Carmustine Wafers Implantation in Patients With Newly Diagnosed High Grade Glioma: Is It Still an Option? |
title_sort | carmustine wafers implantation in patients with newly diagnosed high grade glioma: is it still an option? |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259966/ https://www.ncbi.nlm.nih.gov/pubmed/35812101 http://dx.doi.org/10.3389/fneur.2022.884158 |
work_keys_str_mv | AT ricciardiluca carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT maniniivana carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT cessellidaniela carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT trungusokol carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT piazzaamedeo carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT mangravitiantonella carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT miscusimassimo carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT racoantonino carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption AT iustamara carmustinewafersimplantationinpatientswithnewlydiagnosedhighgradegliomaisitstillanoption |